Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Pharmaceutical firm Pfizer made an equity investment of undisclosed size in Germany-based immunotherapy developer Biontech yesterday through a multi-year research and development collaboration worth up to $425m altogether.
The agreement concerns the development of flu vaccines. Biontech will get a total of $120m in upfront, equity and near-term research funding and up to $305m more if it reaches certain development, regulatory and commercial milestones, as well as double-digit tiered royalty payments on global sales.
Spun out of Johannes…
